← FDA DRUG APPROVALS

FDA ANDA · ANDA062497

DOXY-LEMMON

Sponsor: TEVA

APPLICATION
ANDA062497
TYPE
ANDA
ORIGINAL APPROVAL
1984-08-23
LATEST ACTION
2014-05-19
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

DOXY-LEMMONDiscontinued
DOXYCYCLINE HYCLATE EQ 50MG BASE · CAPSULE · ORAL
DOXY-LEMMONDiscontinued
DOXYCYCLINE HYCLATE EQ 100MG BASE · CAPSULE · ORAL

Approval history

2014-05-19Labeling · Supplement 24 · standardAP
2001-08-30Manufacturing (CMC) · Supplement 23AP
1994-06-23Manufacturing (CMC) · Supplement 19AP
1994-06-23Manufacturing (CMC) · Supplement 17AP
1994-06-23Manufacturing (CMC) · Supplement 18AP
1994-01-26Manufacturing (CMC) · Supplement 21AP
1994-01-26Manufacturing (CMC) · Supplement 22AP
1994-01-26Manufacturing (CMC) · Supplement 20AP
1993-04-01Manufacturing (CMC) · Supplement 16AP
1992-03-26Labeling · Supplement 14AP
1990-10-03Manufacturing (CMC) · Supplement 13AP
1988-05-03Manufacturing (CMC) · Supplement 12AP
1987-11-09Manufacturing (CMC) · Supplement 11AP
1984-08-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →